23:26 , Jun 20, 2019 |  BC Extra  |  Financial News

New listings push IPO pace ahead of last year’s

A spate of biotech IPOs this week in which five companies raised nearly $620 million helped push the biopharma sector’s total haul from NASDAQ listings ahead of 2018’s record pace. Of the five to price...
01:15 , Feb 20, 2016 |  BC Extra  |  Company News

Management tracks

Metabolic play MannKind Corp. (NASDAQ:MNKD; Tel Aviv:MNKD) said Alfred Mann resigned as executive chairman. The board named Lead Director Kent Kresa chairman. Mann will be chairman emeritus and will continue to advise the company. Gastrointestinal...
07:00 , Apr 27, 2015 |  BC Week In Review  |  Company News

GenVec Inc, TheraBiologics deal

GenVec and TheraBiologics partnered to develop cancer therapeutics using GenVec’s gene delivery technology and TheraBiologics’ neural stem cell (NSC) technology. GenVec will contribute vector construction, and TheraBiologics will be responsible for development costs. The first...
08:00 , Feb 23, 2015 |  BC Week In Review  |  Financial News

Arcadia proposes IPO

Arcadia Biosciences Inc. , Davis, Calif.   Business: Agbio/Environmental   Date announced: 2015-02-17   Type: IPO   To be raised: Up to $86.3 million   Shares: TBD   Price: TBD   Underwriters: Credit Suisse; JPMorgan;...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Clinical News

TheraBiologics, University of Chicago, City of Hope preclinical data

In a mouse model of GBM, TBX-03 in combination with temozolomide and radiation increased median survival by about 46%. Additionally, TBX-03 delivered prior to temozolomide and radiation increased median survival by 30%. Data were published...
07:00 , Sep 5, 2011 |  BioCentury  |  Strategy

Back to School: Innovation & collaboration

Since the economic downturn of 2008, doom has become ingrained in the biopharma narrative. According to the mantra, budgets for great science have flatlined. New startups can't find VC money to translate great science because...
07:00 , Jul 18, 2011 |  BioCentury  |  Regulation

Weaving new threads into FDA

FDA organizational changes and personnel appointments announced last week could help depoliticize the agency's decision making, increase its understanding of the way industry operates, and, possibly, improve coordination of drug, biologics and device oversight. The...
07:00 , Mar 28, 2011 |  BioCentury  |  Product Development

Structure vs. function at NCI

Now that the Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network have decided to merge, NCI is down to five adult cooperative groups. But even though the first round of mergers...
08:00 , Feb 28, 2011 |  BioCentury  |  Product Development

Curing cancer trials

A study reported this month in the Journal of the American Medical Association challenges the standard practice of removing cancerous lymph nodes from the underarms of women with breast cancer. For patients, its finding represents...
08:00 , Feb 28, 2011 |  BioCentury  |  Product Development

Curing Cancer Trials: Understanding the co-ops

Since its inception in the 1950s, the cooperative oncology group system has been instrumental in establishing standards for cancer treatment and clinical research. NCI 's Clinical Trials Cooperative Group Program is the nation's largest publicly...